Core Viewpoint - Enhertu (DS-8201) has evolved into a "complete entity" with the recent approval for first-line therapy in HER2+ breast cancer, marking significant progress from its initial approval as a third-line therapy in December 2019 to its current status [1][2] Group 1: Enhertu's Progression - Enhertu's journey includes approvals for HER2+ breast cancer in third-line therapy (December 2019), second-line therapy (January 2021), and now first-line therapy [2] - The first-line therapy approval is in combination with pertuzumab, with expectations for single-agent approval in the future [2] Group 2: Competitive Landscape - The HER2 ADC breast cancer market is approaching a critical phase, with companies like Rongchang Biopharma, Kelun-Biotech, and BaiLi Tianheng adopting various strategies to compete [3][6] - Rongchang Biopharma has focused on differentiated strategies, avoiding direct competition in breast cancer and targeting unmet clinical needs in other indications like gastric cancer [4][6] - Kelun-Biotech has actively pursued HER2+ breast cancer, achieving approval for its product A166 as the first domestic ADC for second-line therapy, leveraging a strategy of gradual advancement [7][9] Group 3: Strategic Approaches - BaiLi Tianheng aims to create a competitive product against Enhertu, with its T-Bren ADC targeting both HER2+ breast cancer and non-small cell lung cancer (NSCLC) [11][14] - HengRui Medicine adopts a multi-cancer strategy, focusing on various indications beyond breast cancer, with its SHR-A1811 ADC already approved for HER2-mutated NSCLC [16][17] Group 4: Differentiated Strategies - Lepu Biopharma's strategy centers on combining its ADC with PD-1 therapies, positioning its products as complementary rather than direct competitors [18][20] - In contrast, YingEn Biopharma has established a global strategy, securing a partnership with BioNTech for its DB-1303 ADC, focusing on unmet needs in endometrial cancer [22][24] Group 5: Future Outlook - The competitive landscape in the HER2 ADC market is intensifying, with companies employing diverse strategies to carve out their niches [26] - The future success in this sector may hinge on the depth of differentiated strategies and the ability to commercialize effectively, rather than solely on product efficacy [26]

Core Insights - The article discusses the upcoming 44th J.P. Morgan Global Healthcare Conference, focusing on the evolving landscape of the healthcare industry and investment opportunities within various sectors [4][28]. - It highlights the shift in investment focus from conceptual discussions to tangible clinical and commercialization pathways, particularly in biotechnology and biopharmaceuticals [6][24]. Group 1: Conference Overview - The conference will feature approximately 530 participating entities, categorized into six main sectors, with biotechnology and biopharmaceuticals representing 44.1% of the total [6]. - The event aims to address key investment questions regarding which sectors are transitioning from theoretical discussions to practical applications and which companies are likely to achieve cross-cycle premium valuations [4]. Group 2: Sector Analysis - **Biotechnology Sector**: Comprises 24.1% of participants, focusing on clinical and regulatory milestones. Companies like BridgeBio and Sarepta are highlighted for their advancements in genetic therapies [13]. - **Biopharmaceutical Sector**: Accounts for 20.0% of participants, with a focus on stable cash flows and research efficiency. Companies such as AbbVie and Amgen are noted for their strong market positions and innovative pipelines [14][15]. - **Medical Devices Sector**: Represents 7.6% of participants, emphasizing the importance of clinical integration and operational efficiency in device adoption. Companies like Intuitive Surgical and Dexcom are recognized for their impactful innovations [17]. - **Healthcare Services and Payments Sector**: Also at 7.6%, this sector faces challenges due to regulatory changes and market dynamics. The focus is on understanding profit structures and cost management [18]. - **Digital Health Sector**: Comprises 3.7% of participants, with companies like Veeva and Teladoc addressing efficiency and cost control in healthcare delivery [19]. - **Diagnostics and Precision Medicine Sector**: Focuses on the integration of diagnostic tools into clinical pathways, with companies like Illumina and Guardant Health leading the way [20][21]. Group 3: Trends and Opportunities - The article notes a significant shift in the role of Chinese CXO companies in the global pharmaceutical innovation ecosystem, moving from cost-driven outsourcing to integral participants in drug development [11]. - The conference reflects a consensus on the need for clear pricing strategies and the importance of clinical, payment, and commercialization pathways in determining company valuations [28][30]. - Chinese pharmaceutical companies are transitioning from domestic validation of technologies to proving their global indispensability, with a focus on international clinical trial efficiency and global registration pathways [22][24][26].

Group 1: Capital Market Developments - The 30th China Capital Market Forum highlighted the importance of the 14th Five-Year Plan for advancing China's modernization and building a strong financial nation, with a focus on risk prevention, strong regulation, and high-quality development [1] - As of January 11, 2026, 108 A-share companies disclosed their 2025 earnings forecasts, with 60 companies showing positive expectations, resulting in a positive growth trend overall [1] - The China Securities Regulatory Commission (CSRC) announced that A-share companies are expected to distribute a record cash dividend of 2.55 trillion yuan in 2025, reflecting improved profitability and cash flow [2] Group 2: Pharmaceutical Innovations - Zai Lab announced the approval of its innovative product, a human thyroid-stimulating hormone beta injection, marking a significant milestone in China's domestic innovative drug development [3] - The National Medical Products Administration (NMPA) plans to enhance support for innovative drugs, focusing on new mechanisms and targets to facilitate their approval and market entry [3] Group 3: Stock Market Performance - The A-share market has seen a significant upward trend since December 17, 2025, with the Shanghai Composite Index surpassing 4100 points, the highest since July 2015 [4] - The market's strong performance is attributed to multiple factors, including policy support, capital influx, and industry trends, with a notable increase in trading volume [5] - Public funds have seen substantial inflows, with over 450 billion yuan entering the market since the beginning of 2026, indicating a shift in investment strategies [6] Group 4: Foreign Investment Trends - There is a growing enthusiasm among global investors for Chinese assets, driven by stable fundamentals, attractive valuations, and ongoing market liberalization [8] - Foreign capital is increasingly focusing on companies with strong R&D capabilities and global presence, particularly in the technology sector [8] Group 5: ETF Market Dynamics - The theme-based ETFs have gained significant traction, with a net inflow of 9.519 billion yuan and an average net value growth rate of 6.6% since the start of 2026 [9] - The public fund industry is moving towards differentiated product offerings, aiming to provide investors with more precise asset allocation tools [9]

Group 1 - The core viewpoint is that the Hong Kong IPO market will not lead to a bear market; instead, increased demand for the Hong Kong dollar may push the currency to its strong-side guarantee, prompting the Hong Kong Monetary Authority to release liquidity in the interbank market, thereby lowering HIBOR rates and boosting the bull market in Hong Kong stocks [1][10] - In 2025, the Hong Kong Stock Exchange is expected to have 117 IPOs raising a total of HKD 285.9 billion, regaining the top position globally after four years. The market anticipates that the IPO fundraising scale in 2026 will continue to be strong, potentially exceeding HKD 300 billion [2][6] - The impact of IPO peaks and fundraising peaks on the Hong Kong stock market is not absolute; historically, these peaks have not reversed the market trend, as seen in previous years like 2010, 2014-2015, 2017, 2020, and 2025 [6][10] Group 2 - The true impact of IPOs on the Hong Kong market may be observed during the six-month lock-up period for cornerstone investors post-listing, with notable declines in the market often coinciding with these unlock periods [16] - However, in 2025, the unlocking of shares did not lead to a market downturn, as the ability for cornerstone investors to sell did not equate to a necessity to sell, allowing new buying power from index funds and foreign investments to offset any selling pressure [16] - There may be a new wave of lock-up share unlocks for mid to large-cap companies (market capitalization over HKD 30 billion) in March and September 2026 [6][16] Group 3 - The short-term stock price increase after inclusion in the Hong Kong Stock Connect is not universally applicable, with historical data showing a low probability of price increases across the full sample [23] - For the Hang Seng Tech Index, institutional investors' presence leads to more accurate predictions regarding index adjustments, with stock prices typically reacting about 30 days before the execution date of adjustments [24] - Following the completion of index adjustments, stock prices usually experience a decline, which typically stabilizes within a week [24]

格隆汇1月12日丨根据联交所最新权益披露资料显示，2026年1月6日，恒瑞医药(01276.HK)获JPMorgan Chase & Co.以每股均价74.6126港元增持好仓112.78万 股，涉资约8415.02万港元。 | 表格序號 | 大股東/董事/最高行政人員名稱 作出披露的 買入 / 賣出或涉及的股 每股的平均價 | | | | 持有權益的股份數目 佔已發行的 有關事件的 | | --- | --- | --- | --- | --- | --- | | | | | | | 請參閱上述*註解)有投票權股(日/月/9 | | | | | | | 分自分市 | | CS20260109E00475 | JPMorgan Chase & Co. | 1101(L) | 1,127,828(L | HKD 74.6126 | 19.193.978(L 7.43(L)06/01/2026 | | | | | | | 6,332,713(S) 2.45(S) | | | | | | | 9,502,137(P) 3.68(P) | 增持后，JPMorgan Chase & Co.最新持好仓数目为19,193, ...

Group 1 - In 2025, out of 650 comparable QDII funds, 619 funds saw an increase in net value, representing 95.2% of the total, while 31 funds experienced a decline [1] - The top-performing fund, Huatai Fuhong Hong Kong Advantage Selection Mixed (QDII) A/C, achieved a remarkable growth of 114.19% and 113.83% respectively [1] - The fund's investment strategy focuses on innovative pharmaceuticals with global competitiveness and high-barrier equipment and consumables [1] Group 2 - The current fund manager of Huatai Fuhong is Zhang Wei, who has extensive experience in the pharmaceutical sector [2] - Six other QDII funds recorded growth exceeding 80%, with four of them managed by E Fund Management, all surpassing 85% growth [2] - The top holdings of these funds include major companies like TSMC, NVIDIA, Google, and Alibaba [2] Group 3 - There are 26 QDII funds with monthly growth rates between 60% and 80%, with the largest being GF Zhongzheng Hong Kong Innovative Medicine ETF (QDII), which had a growth of 66.65% [3] - The Fuguo Blue Chip Selected Stock (QDII) in USD also showed significant growth of 67.99% [4] Group 4 - The bottom-performing QDII funds in 2025 were primarily those focused on oil and gas products, with 10 funds declining over 10% [5] - E Fund Management had four products leading the decline, with losses ranging from 11.64% to 13.59% [5]

Core Insights - The approval of Zeshuo Pharmaceutical's injection of human thyroid-stimulating hormone beta (Zesuning) marks a significant milestone as it becomes China's first innovative product approved for precise assessment post-surgery for differentiated thyroid cancer [1][2] - The Chinese innovative drug industry is experiencing robust growth, with multiple new drugs receiving approval since the beginning of 2026, including innovative drugs from companies like Hengrui Medicine and BeiGene [1][2] - The National Medical Products Administration (NMPA) is enhancing support for innovative drugs, focusing on new mechanisms and targets, and aims to facilitate the "China first launch" of innovative drugs [3][4] Company Developments - Hengrui Medicine's innovative drug, the dual-specific antibody fusion protein Ruilafuzumab α injection, has been approved as the world's first anti-PD-L1/TGF-βRII dual-specificity antibody fusion protein for advanced gastric cancer [1][2] - BeiGene's innovative drug, Sotorasib tablets, has received conditional approval for treating chronic lymphocytic leukemia/small lymphocytic lymphoma and is the first and only BCL2 inhibitor approved for treating mantle cell lymphoma in China [2] - The approval of multiple innovative drugs reflects a significant increase in the number of innovative drugs approved in China, with 76 approved in 2025, surpassing the 48 approved in 2024 [2] Industry Trends - Approximately 20 major new drugs are expected to receive approval in 2026, covering various therapeutic areas such as oncology, infectious diseases, rare diseases, autoimmune diseases, and neurological disorders [3] - The Chinese innovative drug industry is transitioning from a follower to a competitor, with many domestic companies accelerating the development and market entry of groundbreaking innovative drugs [2][3] - The NMPA is implementing reforms to enhance the drug approval process, including the introduction of a data protection system for drug trials and a market exclusivity system for pediatric and rare disease medications [4][5] Policy Support - The NMPA is set to provide comprehensive support across the entire chain of communication, clinical trials, registration, and review processes for innovative drugs [4] - The new medical insurance directory has been implemented, facilitating the inclusion of innovative drugs in hospitals, which alleviates initial payment challenges for high-value innovative drugs [4] - The NMPA is also optimizing the review process for urgently needed foreign drugs, encouraging global simultaneous research and application in China [4][5]

Investment Rating - The report maintains a "Buy" rating for the pharmaceutical and biotechnology industry, specifically recommending stocks such as Micro-Invasive Brain Science, Xiangyu Medical, and Meihua Medical [1]. Core Insights - The report emphasizes the focus on brain-computer interfaces (BCI) as a strategic high ground in global technology, supported by national policies and significant investments [5][19]. - It highlights the approval of innovative drugs and therapies, such as the human thyroid-stimulating hormone beta and the HER2-targeted therapies, which are expected to set new standards in treatment [2][3]. - The report ranks sub-industries in terms of investment potential, with innovative drugs at the top, followed by research services, CXO, traditional Chinese medicine, medical devices, and pharmacies [3][12]. Summary by Sections Industry Trends - The A-share pharmaceutical index has increased by 7.81% year-to-date, outperforming the CSI 300 by 5.03% [11]. - The report notes a significant rise in the healthcare sector, with medical services and devices showing strong performance [11]. Policy Support for Brain-Computer Interfaces - The "14th Five-Year Plan" identifies brain-computer interfaces as a key future industry, with a clear policy support from the government [18]. - The National Health Insurance Administration has established pricing standards for BCI procedures, indicating a commitment to support this emerging field [19][20]. R&D Progress and Company Dynamics - The report lists several companies with promising drug pipelines, including those focusing on PD1 PLUS, ADC, and small nucleic acids, suggesting specific stocks to watch [14]. - It provides a detailed overview of recent approvals and clinical trials, indicating a robust pipeline for innovative therapies [2][3]. Market Performance - The report highlights the significant gains in the pharmaceutical sector, with specific stocks like Innovation Medical and Sanbo Brain Science showing remarkable increases [11]. - It also notes the performance of H-shares, with companies like Jinfang Pharmaceutical-B and Shengnuo Pharmaceutical-B leading the gains [11].

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical industry [4] Core Insights - The pharmaceutical index rose by 7.81% from January 5 to January 9, outperforming the CSI 300 index by 5.03%. The brain-machine interface and AI medical sectors are expected to remain active in Q1 2026, with a strong rebound in innovative drugs, particularly small nucleic acids [5][25] - The report highlights the potential for significant advancements in small nucleic acids in 2026, driven by breakthroughs in liver-targeted delivery technologies and a surge in clinical data readouts [8][22] - The report emphasizes the importance of selecting innovative drug stocks with strong fundamentals and suggests focusing on companies that have undergone sufficient adjustments [5][49] Summary by Sections Industry Performance - The pharmaceutical index saw 443 stocks rise and 25 fall during the week, with notable gainers including Innovative Medical (+61.04%) and Sanbo Brain Science (+56.15%). Conversely, Baohua Pharmaceutical saw a decline of -21.65% [5][26][27] Small Nucleic Acids - 2026 is projected to be a pivotal year for the small nucleic acid sector, with advancements in liver-targeted delivery technologies and a high frequency of clinical data readouts expected [8][22] - Arrowhead's delivery platform has shown promising results in clinical trials, validating the feasibility of RNAi therapies for obesity and other conditions [9][11] Investment Recommendations - The report suggests focusing on companies with leading platform capabilities and differentiated pipeline layouts, such as Rebio Biotech, Yuyuan Pharmaceutical, and Frontier Biotech [20][24] - It also recommends a diversified investment approach, including innovative drugs, brain-machine interfaces, and AI medical technologies [47][48] Market Trends - The report notes that the aging population and increasing healthcare demands are driving growth in the pharmaceutical sector, with a focus on chronic diseases and innovative medical technologies [47] - The report highlights the ongoing trend of domestic companies enhancing their capabilities in the global market, particularly in innovative drug development and medical devices [46][47] Key Companies to Watch - Recommended stocks include China National Pharmaceutical Group, Rebio Biotech, Shanghai Yizhong, and Yuyuan Medical [49]

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry as of January 11, 2026 [3] Core Insights - 2025 marked a significant year for Chinese innovative drugs going overseas, with total transaction amounts reaching $135.655 billion, including $7 billion in upfront payments and 157 deals, setting historical highs [4] - The innovative drug index saw a 35.31% increase in 2025, outperforming the CSI 300 index by 17.65% [4] - The trend of Chinese innovative drugs going global is expected to strengthen in 2026, with significant deals such as the one between Yilian Biotech and Roche for the YL201 project, which includes a $570 million upfront payment [4] - The small nucleic acid drug sector is experiencing breakthroughs, with GSK's Bepirovirsen showing positive results in Phase III trials for chronic hepatitis B, potentially becoming the first drug to achieve functional cure [5] - The report highlights the importance of oral autoimmune drugs, with Takeda's TYK2 inhibitor showing promising results in treating moderate to severe plaque psoriasis [6] - The brain-computer interface technology is entering a critical industrialization phase, with companies like Neuralink set to produce devices in 2026, supported by favorable policies and clinical trials in China [8] - The ZAP-X radiotherapy device is expected to capture a significant market opportunity in China, with the non-invasive tumor radiotherapy market projected to grow from RMB 27.2 billion in 2018 to RMB 59.4 billion by 2024 [10] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry index underperformed the CSI 300 index by 2.13% over the past week, ranking 25th among 31 industry indices [28] - Over the past month, the pharmaceutical industry index also lagged behind the CSI 300 by 5.42%, ranking 27th [29] 2. Pharmaceutical Sector Trends and Valuation - The current PE (TTM) for the pharmaceutical industry index is 36.95, above the five-year historical average of 31.12 [52] 3. Recent Research Achievements - The report includes various deep-dive studies on topics such as the growth of biological agents and oral drugs, and the impact of policy support on the inhalation drug industry [55] 4. Important Industry Policies and News - Recent policies include the issuance of the fourth batch of encouraged generic drug directories by the National Medical Products Administration [57] - Significant news includes GSK's announcement of positive Phase III results for Bepirovirsen and Yilian Biotech's licensing agreement with Roche [58][59]